Traded Sep 17 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Traded Aug 19, 2026 · Filed Aug 21, 2026
The CEO of United Therapeutics sold $125K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$125,397
Shares × reported transaction price
14 days after results of Aug 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Traded Sep 17 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Martine A Rothblatt (Chairperson & CEO) sold ~$295K of United Therapeutics
Scheduled in advanceMartine A Rothblatt (Chairperson & CEO) sold ~$865K of United Therapeutics
Scheduled in advance